Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash & Current Investments (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Cash & Current Investments for 9 consecutive years, with $97.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 3.4% year-over-year to $97.5 million, compared with a TTM value of $97.5 million through Dec 2025, down 3.4%, and an annual FY2025 reading of $97.5 million, down 3.4% over the prior year.
  • Cash & Current Investments was $97.5 million for Q4 2025 at Puma Biotechnology, up from $55.6 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $107.2 million in Q1 2024 and bottomed at $55.6 million in Q3 2025.
  • Average Cash & Current Investments over 5 years is $85.6 million, with a median of $89.1 million recorded in 2023.
  • The sharpest move saw Cash & Current Investments soared 50.47% in 2024, then plummeted 42.5% in 2025.
  • Year by year, Cash & Current Investments stood at $82.1 million in 2021, then dropped by 1.26% to $81.1 million in 2022, then increased by 18.34% to $95.9 million in 2023, then increased by 5.24% to $101.0 million in 2024, then dropped by 3.4% to $97.5 million in 2025.
  • Business Quant data shows Cash & Current Investments for PBYI at $97.5 million in Q4 2025, $55.6 million in Q3 2025, and $96.0 million in Q2 2025.